Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for kids with arthritis: Long-Term drug study launches

NCT ID NCT07553182

First seen May 07, 2026 · Last updated May 22, 2026 · Updated 3 times

Summary

This study looks at the long-term safety and effectiveness of the drug filgotinib in children aged 8 to 17 with juvenile idiopathic arthritis (JIA). Participants must have already completed a previous filgotinib study and shown improvement. The goal is to see if the drug continues to control disease symptoms over time and to monitor any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS (JIA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asklepios Klinik Sankt Augustin GmbH

    NOT_YET_RECRUITING

    Sankt Augustin, 53757, Germany

    Contact

  • Bicetre Hospital

    NOT_YET_RECRUITING

    Le Kremlin-Bicêtre, 94270, France

    Contact

  • Great Ormond Street Hospital for Children

    NOT_YET_RECRUITING

    London, WC1N 3JH, United Kingdom

    Contact

  • Hamburger Zentrum für Kinder- und Jugendrheumatologie

    RECRUITING

    Hamburg, 22081, Germany

    Contact

Conditions

Explore the condition pages connected to this study.